

## THRU ONLINE FILING

December 20, 2019

BSE Limited Phiroze Jeejeebhoy Towers 27<sup>th</sup> Floor, Dalal Street Mumbai 400 023

The National Stock Exchange of India Ltd. Exchange Plaza, 5<sup>th</sup> Flr, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051.

## <u>Ipca and Medicines for Malaria Venture to develop a novel alternative, affordable prophylaxis for use in malaria-endemic countries</u>

Ipca Laboratories Ltd. (Ipca), a market leader in antimalarials and a global pharmaceutical manufacturer has entered into an agreement with a leading product development partnership, Medicines for Malaria Venture (MMV), to co-develop a novel antimalarial co-formulation named "Atoguanil".

Atoguanil, based on proprietary Ipca technology, contains the active pharmaceutical ingredients atovaquone and proguanil. Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone—proguanil based products in malaria-endemic countries. Atoguanil has the potential to provide a lower cost alternative, making such products more accessible to people living in malaria-endemic countries for prophylaxis.

## About Ipca Laboratories Ltd.

Ipca, a market leader in antimalarial segment in India, is a research driven innovative pharmaceutical Company that develops, manufactures and markets a broad range of pharmaceutical APIs and finished dosage forms globally. The group employs over 13,000 people worldwide, including about 500 scientists engaged in R & D and is dedicated to developing and marketing quality medicines meeting all global regulatory standards.

This is for your information and record.

Thanking you

Yours faithfully For Ipca Laboratories Limited

Harish P. Kamath

Corporate Counsel & Company Secretary